41 results about "Dihydrotestosterone" patented technology

A natural supplement is described herein. The supplement includes a therapeutically effective amount of a composition. The composition includes: at least two materials having analgesic activity, at least two materials having anti-inflammatory activity, at least two materials having antioxidant activity, at least two materials having anti-neuralgic activity, at least two materials having blood circulation promotion activity, at least one material having Dihydrotestosterone (DHT) blocking activity, and at least one material having hair thickening activity or hair growth activity. The natural supplement not only provides pain relief from a variety of symptoms, but also promotes hair growth.

The invention discloses an androgen alopecia slow-release therapeutic agent. The androgen alopecia slow-release therapeutic agent is rhizoma drynariae extracellular vesicles; or the rhizoma drynariae extracellular vesicles are compounded with minoxidil. The androgen alopecia slow-release therapeutic agent can effectively inhibit human hair follicle cell apoptosis and oxidative stress induced by dihydrotestosterone, and has excellent hair follicle targeting property and safety; the invention belongs to the technical field of medicine.

The invention provides an application of dimethylformamide in preparation of a product for preventing or treating androgenetic alopecia. When DHT (dihydrotestosterone) is used for constructing an androgenetic alopecia mouse model, it is found that after 30 mg / kg / d of dimethylformamide is given, the growth period of hair follicles is obviously accelerated, the hair density of a model mouse is effectively increased, and the hair recovery time is shortened. Organ-like experiments find that after the dimethylformamide treatment, the aggregation and fusion of the organ-like are obviously increased, and the NRF2 expression is also obviously enhanced. Therefore, the dimethylformamide has an effect of promoting the recovery of androgenetic alopecia and has the potential of being developed into corresponding medicines or cosmetics.

The present invention relates to a method for detecting steroid hormones in serum, comprising the following steps: (1) adding 0.1 to 20 mg of a magnetic solid phase extractant to each milliliter of a sample to be tested, mixing, magnetically separating, and removing liquid; adding a washing solution, mixing, magnetically separating, and removing liquid; adding an eluent for elution, mixing, magnetically separating, and collecting the eluent to obtain a test solution; (2) detecting the hormone content in the test solution by liquid chromatography and tandem mass spectrometry; wherein the hormone is selected from any one of testosterone, androstenedione, dihydrotestosterone, dehydroepiandrosterone sulfate, and 17α-hydroxyprogesterone or a combination thereof; the magnetic solid phase extractant comprises a magnetic core ferrosoferric oxide, a middle layer structure silica wrapping the magnetic core, and an outer layer mesoporous structure, wherein the outer layer mesoporous structure is selected from any one of polystyrene and polystyrene divinylbenzene or a combination thereof. The present invention has the characteristics of good stability, high accuracy and sensitivity, strong specificity, high recovery rate, simple and controllable operation, fast analysis speed, etc., and can be used for simultaneous quantitative detection of multiple hormones in clinical practice.

Disclosed are pharmaceutical and cosmetic compositions that include 5 Alpha Dihydrotestosterone (or alternatively, 5α-DHT, 5 Alpha-DHT, 5 Alpha DHT, 5a-DHT, DHT), and associated methods of use and treatment that can be used alone or in combination with other treatments to provide, improve, or promote general well-being and health, including mental health, in a subject. In particular the compositions, methods, and uses can provide, promote, support, and / or improve outcomes associated with gender reassignment, gender transitioning, and / or gender-affirming therapy in a subject who may be in need thereof.

Provided is the composition capable of effectively exerting an effect on a change in a hormone balance. A composition for inhibiting the decrease in endogenous testosterone and / or dihydrotestosterone, the composition comprising Cordyceps militaris derived from Samia cynthia ricini and / or its extract is prepared.

The invention provides a traditional Chinese medicine composition for preventing hair loss and promoting hair growth and application thereof, and relates to the technical field of hair loss prevention and promoting hair growth, the traditional Chinese medicine composition is composed of Chinese doughnut, cockscomb, albizia flower, Chinese honey locust, schizonepeta, lithospermum, polygonum multiflorum, prepared rehmannia root, notopterygium root, radix angelicae pubescentis, ruddle and periostracum cicada; in-vitro experiments show that the traditional Chinese medicine composition can promote proliferation of human dermal papilla cells HDPC, relieve the damage degree of HDPC and induce cycle transformation of hair follicles, so that the effect of promoting hair growth is achieved; animal experiments show that the traditional Chinese medicine composition can significantly increase the number of hair follicles and the thickness of skin and dermis fat of mice, reduce the levels of mouse serum IL-2, TNF-alpha and TGF-beta1 and reduce the levels of testosterone, dihydrotestosterone and estradiol in mouse skin tissue, so that hair follicle fibrosis is inhibited, the growth period of hair follicles is accelerated, the growth period is prolonged, the hair loss phenomenon is improved, and the hair loss rate is increased. The hair growth is promoted.

The present disclosure describes a method for preventing or treating an abnormal mammary gland cytopathy characterized by cell proliferation in a subject. The method comprises administering to the subject an effective amount of an androgen agent in combination with an effective amount of an aromatase inhibitor, increasing the concentration of the androgen agent in serum to a level to increase the intramammary concentration of androgen in the mammary gland resulting from the action of 5 alpha-reductase on the androgen agent, the increased intramammary concentration of the androgen induces inhibition of c-Myc and / or mTOR expression or activity in the mammary gland associated with a lower intramammary concentration of the androgen. The increase in the serum concentration of the androgen agent and the increase in the intramammary concentration of the androgen are maintained for a predetermined period of time without substantially increasing the concentration of the androgen in the serum of the subject. Furthermore, the use of the aforementioned androgen and aromatase inhibitors for reducing the risk of breast cancer progression to hormone-resistant breast cancer, reducing the risk of HER2-positive breast cancer becoming insensitive to targeted HER-2 anti-cancer drug therapy, and for inducing inhibition of c-Myc and / or mTOR expression and / or activity is also described. In embodiments, the androgen agent may be testosterone and androgen 5 [alpha]-dihydrotestosterone (DHT).

The present invention relates to a composition for preventing, ameliorating or treating benign prostatic hyperplasia, containing a Hovenia dulcis extract as an active ingredient. Specifically, the Hovenia dulcis extract of the present invention was confirmed to inhibit the proliferation of hyperproliferative prostatic cells induced by dihydrotestosterone (DHT), which is a male hormone, and reduce prostate weight in an animal model with induced benign prostatic hyperplasia, and thus can be effectively used as a composition for preventing, ameliorating or treating benign prostatic hyperplasia.

Novel chemical agents are described herein. More specifically, a novel inhibitor of 17β-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In a particular embodiment, the inhibitor of 17β-HSD7 has the following structure: (Formula I) A process for producing the novel inhibitors of 17β-HSD7 and their use in the manufacture of pharmaceutical formulations and / or combinations is also disclosed.

The application relates to the technical field of biology, and discloses a method for inducing a cell line of immortalized musk deer scent glands to synthesize dihydrotestosterone, wherein the cell line is obtained by transfecting a primary musk deer scent gland epithelial cell with a lentivirus carrying an SV40 Large T antigen and performing resistance screening; the cell line is in an epithelial cell form and stably expresses keratin 18, cholesterol side chain cleavage enzyme, 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase. Through lentivirus-mediated SV40 Large T antigen transfection, the primary musk deer scent gland epithelial cell breaks through the limit of replicative senescence and obtains unlimited proliferation capacity, effectively overcomes the defects that the primary cell is prone to fibrosis and rapidly loses metabolic function during in-vitro culture, provides a standardized cell model with a clear genetic background and persistent metabolic activity for biological manufacturing of dihydrotestosterone, and relieves the dependence on endangered animal live resources.

The present invention relates to a composition for preventing or treating male pattern hair loss by adsorption and / or removal of dihydrotestosterone (DHT), and uses thereof, wherein the composition comprises a metal-organic framework, which penetrates hair follicles and, by adsorbing and / or removing DHT, can exhibit preventive or therapeutic effects against the progression of hair loss. In addition, when the composition is applied to the scalp as a hair serum or a hair cream comprising the metal-organic framework, the metal-organic framework penetrates hair follicles and can continuously adsorb / remove DHT that is continuously released in the body, and the metal-organic framework that has adsorbed and / or removed DHT can be discharged to the outside as the hair grows.

The application provides application of echinocystic acid in preparation of a 5alpha-reductase type II inhibitor product. In-vitro tests prove that the echinocystic acid has obvious inhibitory effect on 5alpha-reductase type II activity; experimental testosterone-induced androgenic alopecia mouse models prove that the echinocystic acid can promote hair growth of the mice and reduce dihydrotestosterone content in the skin of the mice, and can be used for preparing a product for inhibiting 5alpha-reductase type II activity and treating androgenic alopecia.

The invention discloses application of a semen nigellae extract in preparation of a product for preventing and / or treating androgenetic alopecia. The total content of nigella alkaloid and nigella alkaloid 4-O-sulfite in the nigella seed extract is not less than 2%. The preparation process comprises the following steps: degreasing nigellum nigrum medicinal material powder with petroleum ether, extracting with an acidic aqueous solution, and enriching with macroporous adsorption resin and specifically purifying with anion exchange resin in sequence. Experiments show that the extract can most significantly reduce the levels of testosterone (T), dihydrotestosterone (DHT) and creatinine (Cr) in an androgenetic alopecia model mouse body, increase the level of estradiol (E2) and effectively promote back hair regeneration, and the effect of the extract is significantly superior to that of a water extract, an alcohol extract and a positive control drug. The extract is clear in component and controllable in quality, can be used for preparing medicines or wash supplies with multi-target anti-hair loss and hair growth functions, and provides a novel efficient natural raw material for treating androgenetic alopecia.

Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.

The invention discloses an oil control composition for regulating sebaceous glands and a preparation method and application thereof, and belongs to the technical field of cosmetics, the oil control composition for regulating sebaceous glands comprises the following components in parts by mass: 0.5-10 parts of 10-hydroxydecanoic acid, 5-25 parts of sarcosine and 5-50 parts of an oil control agent, the oil control agent comprises a Thermus thermophilus fermentation product, the mass percentage content of the Thermus thermophilus fermentation product in the oil control agent is not less than 80%; the 10-hydroxydecanoic acid, the sarcosine and the oil control agent are combined according to the specific mass parts to obtain the composition with an excellent oil control effect, and the composition can effectively inhibit 5 alpha-reductase in sebaceous gland cells, reduce conversion of testosterone to dihydrotestosterone (DHT), inhibit sebaceous gland secretion and reduce grease accumulation on the skin surface, so that the sebaceous gland skin-care effect is improved, and the skin-care effect is improved. Pore blockage is reduced, the number of active sebaceous gland bodies is reduced, the secretion activity of the active sebaceous gland bodies is reduced, and skin grease is effectively reduced.

The invention provides an application of echinocystic acid in preparation of a type II 5 alpha-reductase inhibitor product. In-vitro tests prove that echinocystic acid has an obvious inhibition effect on the activity of II type 5 alpha-reductase; experimental testosterone-induced androgenic alopecia mouse models prove that echinocystic acid can promote mouse hair growth and reduce the content of dihydrotestosterone in mouse skin, and can be used for preparing products for treating androgenic alopecia by inhibiting the activity of type II 5alpha-reductase.

The invention discloses application of ruscogenin in preparation of products for preventing and / or treating alopecia, and belongs to the technical field of medicines. The invention finds that ruscogenin can inhibit the activity of 5alpha-reductase, inhibit death of human dermal hair follicle nipple cells caused by dihydrotestosterone, promote proliferation of the human dermal hair follicle nipple cells and promote hair growth. The ruscogenin can be applied to preparation of products for preventing and / or treating alopecia, new application of the ruscogenin is provided, and a new choice is provided for preventing and treating alopecia.

The invention discloses a siRNA preparation for treating benign prostatic hyperplasia, and belongs to the technical field of biological pharmacy. By analyzing mRNA sequences of human and rat SRD5A2, two siRNA sequences for silencing SRD5A2 protein expression are designed and synthesized. The two kinds of siRNA transfect human normal prostate matrix immortalized cells through lipidosome, and both siRNA-1 and siRNA-2 can achieve a good SRD5A2 gene silencing effect. Two siRNA-liposome compounds are intravenously injected into a benign prostatic hyperplasia model rat induced by testosterone propionate, and the siRNA-1 and the siRNA-2 can effectively silence the expression of the SRD5A2 in the rat body. After a prostatic hyperplasia model rat is treated by the two siRNAs, the content of dihydrotestosterone DHT in serum is remarkably reduced compared with that of an untreated model group, and the prostate index is also remarkably reduced.

The invention belongs to the technical field of biomedical cosmetics, and discloses a double-target 5alpha-reductase and adiponectin receptor cyclic peptide as well as application and a preparation method thereof. The cyclic peptide is formed by cyclizing three amino acid units, namely arginine, phenylalanine and tyrosine through peptide bonds, and comprises pharmaceutically acceptable salts, solvates, stereoisomers or isotope labels of the cyclic peptide. The compound reduces generation of dihydrotestosterone by inhibiting 5alpha-reductase, activates an adiponectin receptor AdipoR pathway to promote energy metabolism and proliferation of hair papilla cells, and realizes double-target synergistic anti-alopecia. The invention also discloses application of the cyclopeptide in preparation of medicines or cosmetics for preventing or treating alopecia and a solid-phase synthesis preparation method. Through double-target synergistic interaction, the hair follicle cell proliferation rate can be remarkably increased at extremely low concentration, and the dosage is reduced compared with that of a traditional medicine; the composition is constructed by adopting physiological amino acid, has no systemic sex hormone side effect during local external use, and is high in safety.

The invention provides an application of wedelolactone in preparation of a type II 5 alpha-reductase inhibitor product. In-vitro tests prove that wedelolactone has an obvious inhibition effect on the activity of type II 5 alpha-reductase; experimental testosterone-induced androgenic alopecia mouse models prove that wedelolactone can promote mouse hair growth and reduce the content of dihydrotestosterone in mouse skin, and can be used for preparing products for treating androgenic alopecia by inhibiting the activity of type II 5 alpha-reductase.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The invention relates to a biomarker for diagnosing 17 alpha-hydroxylase deficiency and application of the biomarker. The biomarkers comprise 5 [alpha]-dihydroprogesterone, 17 hydroxyl-dihydroprogesterone, 17 hydroxyl-tetrahydroprogesterone, androsterone, androstanediol and dihydrotestosterone. According to the method disclosed by the invention, a biomarker for diagnosing the 17 alpha-hydroxylase deficiency is deeply mined and analyzed based on a liquid chromatography-mass spectrometry technology, an efficient screening tool is further developed, and high-specificity, high-sensitivity and high-accuracy auxiliary screening of the 17 alpha-hydroxylase deficiency is realized.

The present invention relates to a composition for preventing, ameliorating or treating benign prostatic hyperplasia, containing Hovenia dulcis honey as an active ingredient. Specifically, the Hovenia dulcis honey of the present invention suppresses the proliferation of prostate cells that are hyperproliferated by dihydrotestosterone (DHT), which is a male hormone, and has the effect of reducing prostate weight in an animal model with induced benign prostatic hyperplasia, and thus can be effectively used as a composition for preventing, ameliorating or treating benign prostatic hyperplasia.

This invention relates to the field of pharmaceutical technology and discloses the application of mitochondrial quinone in the intervention and treatment of androgenetic alopecia. This invention explores the application and related molecular mechanisms of mitochondrial quinone in alleviating hair loss in mice stimulated by DHT, clarifying the effectiveness of mitochondrial quinone in inhibiting abnormal hair follicle growth and promoting hair regeneration in mice induced by dihydrotestosterone. This provides experimental evidence for the clinical application of mitochondrial quinone in the intervention and treatment of hair loss diseases, especially androgenetic alopecia, and offers another safe and effective substance for the effective prevention and treatment of androgenetic alopecia.

This invention relates to the field of biomedicine, specifically disclosing an antibody for treating benign prostatic hyperplasia (BPH) and its applications. The antibody is a nanobody containing a complementary determinant region (CDR) sequence as shown in SEQ ID NO:5. This invention provides a method for preparing the antibody and demonstrates that it effectively antagonizes the binding of GnRH to GnRHR, thereby inhibiting cAMP production mediated by the GnRH signaling pathway and reducing the levels of testosterone, dihydrotestosterone, and luteinizing hormone. In vivo pharmacodynamic experiments show that the antibody provided by this invention can significantly improve the prostate weight / body weight ratio in a rat model of benign prostatic hyperplasia, exhibiting a good therapeutic effect on BPH and providing a new candidate drug for the clinical treatment of BPH.

The present invention relates to a pharmaceutical composition for preventing or treating benign prostatic hyperplasia, including mixed extracts of Curcumae radix and Syzygii flos as an effective component. The mixed extracts were found to inhibit the expression of dihydrotestosterone, androgen receptors, prostate-specific antigens, proliferating cell nuclear antigen (PCNA), cyclin B1, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); and to have less adverse side effects compared to an existing benign prostatic hyperplasia drug, finasteride, and thus may be beneficially used for the prevention or treatment of benign prostatic hyperplasia.

A composition comprising at least one DNAzyme capable of cleaving 5 Alpha reductase type 2 (5AR2) mRNA and / or at least one DNAzyme capable of cleaving 5 Alpha reductase type 1 (5AR1) mRNA for use in treating a disease associated with over-expression of Dihydrotestosterone (DHT) is disclosed. Cosmetic compositions are also disclosed.

This invention provides a composition containing lactic acid bacteria and its use in lowering dihydrotestosterone and improving hyperandrogenemia. The composition can lower dihydrotestosterone and improve androgenemia. The lactic acid bacteria comprise *Lactobacillus helveticus* GKS3, *Lactobacillus brevis* GKL9, *Lactobacillus johnsonii* GKJ2, *Pediococcus acidilactici* GKA4, or a combination thereof.

The invention discloses a ribonucleic acid and natural product combined anti-hair loss composition and application thereof. The invention relates to a composition for treating androgenetic alopecia, which comprises a cupressus sempervirens cones extract (CSE), 5, 7-dihydroxyflavone (DHF) and a small interfering RNA (siRNA) which is specifically chemically modified and is targeted to an androgenetic alopecia key gene SRD5A2 and / or AR. Cell and animal models verify that the composition with the optimal proportion of the components has the effects of promoting hair growth, increasing the number of hair follicles, reducing the levels of local dihydrotestosterone (DHT) and inflammatory factors and the like, and the effects of the composition are remarkably superior to those of a traditional compound and a positive control. Based on this, the invention provides a new scheme for preventing and / or treating androgenetic alopecia.